PMID- 26298024
OWN - NLM
STAT- MEDLINE
DCOM- 20160818
LR  - 20220409
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 109
IP  - 10
DP  - 2015 Oct
TI  - Physical activity in COPD patients decreases short-acting bronchodilator use and 
      the number of exacerbations.
PG  - 1320-5
LID - S0954-6111(15)30033-0 [pii]
LID - 10.1016/j.rmed.2015.08.001 [doi]
AB  - BACKGROUND: Physically inactive patients with chronic obstructive pulmonary 
      disease (COPD) exhibit higher rates of exacerbations and symptoms of dyspnoea 
      than active patients. Whether the use of COPD medication explains these 
      differences is not known. AIM: This study evaluated differences in the use of 
      COPD medication and the number of exacerbations due to physical activity. 
      METHODS: A COPD cohort (N = 719) was followed through medical records to identify 
      hospital admissions, and exercise activity was evaluated using mailed 
      questionnaires. The national drug reimbursement registry identified drug 
      purchases for one year. RESULTS: The use of maintenance therapies, such as 
      long-acting muscarinic antagonists (LAMAs), long-acting beta agonists (LABAs), 
      inhaled corticosteroids (ICS), and theophylline, did not differ significantly 
      between physically active (N = 346) and inactive (N = 355) COPD patients. The 
      cumulative dose of salbutamol (85 vs. 218 mg, adjusted P = 0.01) and oral 
      corticosteroids (OCS) (621 vs. 1068 mg, adjusted P = 0.02) were significantly 
      higher in inactive patients, regardless of disease severity. LABAs, LAMAs, and 
      ICS were used in reduced doses in both patient groups compared to daily defined 
      doses (DDD). Physical activity was independently associated with the number of 
      hospital admissions and the use of OCS and short-acting bronchodilators. 
      CONCLUSION: Physical inactivity in COPD was not associated with poorer use of 
      maintenance therapies. In contrast, inactivity was independently associated with 
      the number of exacerbations measured by hospital admissions and the use of OCS 
      and short-acting symptom-relieving medications.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Katajisto, Milla
AU  - Katajisto M
AD  - Clinical Research Unit of Pulmonary Diseases and Division of Pulmonology HUCH 
      Heart and Lung Center, University of Helsinki and Helsinki University Hospital, 
      Finland. Electronic address: milla.katajisto@fimnet.fi.
FAU - Koskela, Jukka
AU  - Koskela J
AD  - Clinical Research Unit of Pulmonary Diseases and Division of Pulmonology HUCH 
      Heart and Lung Center, University of Helsinki and Helsinki University Hospital, 
      Finland.
FAU - Lindqvist, Ari
AU  - Lindqvist A
AD  - Clinical Research Unit of Pulmonary Diseases and Division of Pulmonology HUCH 
      Heart and Lung Center, University of Helsinki and Helsinki University Hospital, 
      Finland.
FAU - Kilpelainen, Maritta
AU  - Kilpelainen M
AD  - Department of Pulmonary Diseases and Clinical Allergology, Turku University 
      Hospital and University of Turku, Finland.
FAU - Laitinen, Tarja
AU  - Laitinen T
AD  - Department of Pulmonary Diseases and Clinical Allergology, Turku University 
      Hospital and University of Turku, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150806
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Muscarinic Antagonists)
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adrenergic beta-2 Receptor Agonists/therapeutic use
MH  - Aged
MH  - Albuterol/therapeutic use
MH  - Bronchodilator Agents/*therapeutic use
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Dyspnea/drug therapy/physiopathology
MH  - Female
MH  - Forced Expiratory Volume/physiology
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Motor Activity/drug effects/*physiology
MH  - Muscarinic Antagonists/therapeutic use
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/*physiopathology
MH  - Quality of Life
MH  - Spirometry/methods
OTO - NOTNLM
OT  - COPD
OT  - Maintenance medication
OT  - Physical activity
OT  - Rescue medication exacerbation
EDAT- 2015/08/25 06:00
MHDA- 2016/08/19 06:00
CRDT- 2015/08/24 06:00
PHST- 2015/04/25 00:00 [received]
PHST- 2015/07/07 00:00 [revised]
PHST- 2015/08/02 00:00 [accepted]
PHST- 2015/08/24 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2016/08/19 06:00 [medline]
AID - S0954-6111(15)30033-0 [pii]
AID - 10.1016/j.rmed.2015.08.001 [doi]
PST - ppublish
SO  - Respir Med. 2015 Oct;109(10):1320-5. doi: 10.1016/j.rmed.2015.08.001. Epub 2015 
      Aug 6.